Eli Lilly has agreed to acquire hearing loss gene therapy developer Akouos for up to $610 million, with an initial payment of $487 million and potential milestone-based payments of up to $123 million.

A comprehensive review of ALS drug development reveals 53 new drug candidates in clinical trials between 2020-2022, with 13 compounds advancing to Phase 3 trials and showing promising therapeutic potential.

GSK has announced a $1.4 billion acquisition of Aiolos Bio, including a $1 billion upfront payment, to secure AIO-001, a promising long-acting anti-TSLP antibody for severe asthma treatment.

One-year outcomes from the BouNDless open-label extension study confirm the long-term efficacy of ND0612 in managing motor fluctuations in Parkinson's disease.

A Canadian study found no significant difference in treatment persistence between IBD patients switched to infliximab biosimilars and those remaining on the reference product.

India's drug regulatory watchdog, CDSCO, is considering centralizing antibiotic approvals to prevent the spread of unsafe antibiotics and irrational combinations.

Sammy Basso, a prominent advocate and researcher for progeria, passed away at the age of 28 due to suspected cardiovascular complications.

A study in Brazil shows bedaquiline-containing regimens (BCR) are associated with favorable outcomes in rifampicin-resistant/multidrug-resistant tuberculosis (RR/MDR-TB) treatment.

A new study reveals that specific autoantibodies in the nasal cavities of COVID-19 patients are linked to milder symptoms and faster recovery.

Researchers found that individuals with Long COVID symptoms are twice as likely to have detectable SARS-CoV-2 proteins in their blood, indicating persistent infection.

The FDA has approved the first single-dose, generic formulation of paclitaxel (Abraxane) for intravenous use in metastatic breast cancer patients.

Darolutamide plus androgen deprivation therapy (ADT) significantly reduced the risk of radiological progression or death by 46% in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Aileron Therapeutics presented Phase 1b trial data for LTI-03 at ICLAF, showing a positive trend in biomarkers related to IPF progression.

The FDA has released draft guidance on multiregional clinical trials (MRCTs) in oncology, aiming to streamline drug development and regulatory review processes.

Researchers utilized a comprehensive biomarker and modeling approach to optimize the dose of BI 836880, a VEGF/Ang-2 inhibitor, in advanced solid tumors.

A clinical trial is underway to assess the efficacy of benfotiamine in increasing thiamine levels in the brains of patients with early Alzheimer's disease.

AC Immune's ACI-7104.056 Phase 2 trial for Parkinson's disease is set to report interim safety and immunogenicity data by the end of 2024.

Kodiak Sciences' GLOW1 Phase 3 study of tarcocimab tedromer (KSI-301) in diabetic retinopathy shows a 29-fold increase in disease improvement rates.

Ananda Developments' MRX2 and MRX2T formulations selected for two Phase III trials targeting drug-resistant epilepsies, funded by NIHR and NHS England.

Ocular Therapeutix accelerates the SOL-1 Phase 3 trial for Axpaxli in wet AMD, expecting full enrollment by the end of 2024.